After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines destined for the US market to be produced within the country.

FDA plans to replace animal testing with AI – “Paradigm shift”

The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met with skepticism from the National Association for Biomedical Research.

From pharmacist to life science podcaster – Magnus Lejelöv uses his voice as a tool

Magnus Lejelöv has more than 20 years of experience in the pharmaceutical industry and has conducted nearly two hundred interviews with healthcare professionals on his podcasts.

RFK Jr: I september vet vi vad som orsakar autism

USA ska identifiera orsaken till autism – och det ska vara gjort till september i år. Det säger USA:s hälsominister Robert F. Kennedy Jr., som därmed sätter en synnerligen tajt deadline för att lösa en gåta som gäckat seriösa forskare i decennier.

Europeiska läkemedelsaktier rasar efter Trumps tullhot

Europeiska läkemedelsbolag faller kraftigt efter att USA:s president Donald Trump flaggat för att stora tullhöjningar är på gång mot branschen.

EQT säljer Karo Healthcare för 27 miljarder

Riskkapitalbolaget KKR förvärvar det svenska konsumenthälsobolaget Karo Healthcare från EQT.

Hallå där... Björn Arvidsson, ny forsknings- och innovationsdirektör i Region Uppsala

Tau-targeted Alzheimer's drug gets Fast Track designation in the USA

Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

Tau-inriktat alzheimerpreparat får snabbspår i USA

Amerikanska Biogens alzheimerkandidat BIIB080 har beviljats ”Fast Track” – ett snabbspår – av den amerikanska läkemedelsmyndigheten FDA.

Success for Genmab's antibody-drug conjugate

The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.

Vaccine skeptic David Geier to lead study on link to autism

The American government is to launch a study on whether vaccines cause autism – and has appointed a well-known vaccine skeptic to lead the analysis.

Aqilion's licensing journey: From Merck partnership to new opportunities

Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO Sarah Fredriksson and is directed at biotech companies aiming to find a good licensing partner.

Positive trend for Swedish medtech exports – “We have new markets that are huge”

In 2024, Swedish exports of pharmaceuticals decreased for the first time in several years. However, the trend for medical technology looks brighter. During a seminar, it was discussed how Swedish life science companies can navigate the changing global situation.

Career coach on salaries: “There is no right or wrong”

What is a reasonable salary for my job? It's a question we all ask ourselves. But how important is a higher salary really? Career coach Tina Persson believes this is an important consideration.

A tiny animal with great importance

From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious career – as an increasingly important model organism in medical research.

Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

The art of successful licensing – “A lot has to align”

Sharp research, strong data and a high level of innovation are all very good, but more than that is required to achieve the goal of many biotechnology companies: to succeed with a licensing deal.

Doge backar om nedläggning av viktigt FDA-labb

Trumpadministrationen drar efter kritik tillbaka beslutet att stänga ett av FDA:s viktigaste laboratorier för läkemedelskontroll.

Karriärcoachen om löner: ”Det finns inget rätt eller fel”

Vad är en rimlig lön för mitt jobb? Det är en fråga vi alla ställer oss. Men hur viktigt är det egentligen med högre lön? Det tycker karriärcoachen Tina Persson man bör fundera över.

Ytterligare läkemedelskandidat mot Alzheimers droppas

Ett litet schweiziskt biotechbolag avbryter en fas II-studien med sin läkemedelskandidat mot Alzheimers sjukdom. Beskedet kommer inte långt efter att Biogen och Eli Lilly gjort likadant med kandidater i samma klass.

Security flaw in Swedish breast cancer screening software – woman passed away

A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 out of 21 regions in Sweden. It is also used in neighbouring Nordic countries. “Extremely serious,” says the Sectra CEO to Medtech Magazine.

Developing rapid diagnostics for sepsis – “Every hour counts”

Finding the right antibiotic in the right dose – with an ultra-fast analysis method. Gradientech's product solution is currently used in routine diagnostics at several hospitals in Europe – and the next target is the US market.

Health politician Lina Nordquist: ”I find it hard to be idle”

of Parliament for the Liberals and their spokesperson on healthcare policy, to have a conversation about reality, politics, and the need for writing.

Pfizer värvar FDA-topp – kritiseras hårt

Läkemedelsjätten Pfizers rekrytering av Patrizia Cavazzoni, tills helt nyligen toppchef vid FDA, som ny medicinsk chef får frän kritik från flera håll.